Onset of Type 1 Diabetes Mellitus During Pegylated-interferon Alfa and Ribavirin Therapy for Chronic Hepatitis C Virus Infection

被引：1

作者：

Ranganathan, Raghini ^{[1
]}

Janarthanan, Krishnaveni ^{[1
]}

Rajasekaran, Senthilkumar ^{[1
]}

机构：

[1] PSG Inst Med Sci & Res, Dept Gastroenterol, Coimbatore 641004, Tamil Nadu, India

来源：

JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY | 2012年 / 2卷 / 01期

关键词：

Diabetes mellitus; hepatitis C virus; interferon;

D O I：

10.1016/S0973-6883(12)60089-9

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

A 16-year-old female was treated with pegylated-interferon (PEG-IFN) alfa (alpha)-2b and ribavirin combination therapy for chronic hepatitis C virus (HCV) infection. She attained rapid virological response. She presented with diabetic ketoacidosis after 41 weeks of therapy. Anti-glutamic acid decarboxylase antibodies and islet cell antibodies were negative. Her fasting serum C-peptide level was <0.1ng/mL, and the treatment course was completed. This case underlines the importance of periodic plasma glucose monitoring in patients during and after PEG-IFN and ribavirin therapy.

引用

下载

页码：86 / 87

页数：2

共 50 条

[31] Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to prior therapy with either interferon alfa and ribavirin or pegylated interferon and ribavirin
Chen, K
Seraphin, P
Murphy, L
Shah, N
HEPATOLOGY, 2005, 42 (04) : 670A - 670A
[32] A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin
Selvapatt, Nowlan
Habibi, Maximillian S.
Brown, Ashley
JOURNAL OF MEDICAL VIROLOGY, 2015, 87 (10) : 1716 - 1721
[33] Manifestation of type I diabetes mellitus in a patient with hepatitis C during therapy with α-interferon and ribavirin
Figge, K
Reiser, M
Schmiegel, W
Nauck, MA
DIABETOLOGIA, 1999, 42 : A102 - A102
[34] Effectiveness of Triple Therapy With Boceprevir, Pegylated Interferon, and Ribavirin in Veteran Patients With Chronic Hepatitis C Virus Infection
Andrade, Christian
Patel, Brijesh
Muhammad, Adnan
Vidyarthi, Gitanjali
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S178 - S178
[35] HCV core antigen is a useful predictor during pegylated-interferon/ribavirin therapy in patients with hepatitis C virus genotype 1b
Fan, Zhijuan
Liu, Junfeng
Wang, Fengmei
Liu, Jingmin
Ding, Xian
Liu, Shuye
MEDICINE, 2019, 98 (10)
[36] Leukocytoclastic vasculitis during pegylated interferon and ribavirin treatment of hepatitis C virus infection
Adisen, Esra
Dizbay, Murat
Hizel, Kenan
Ilter, Nilsel
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2008, 74 (01): : 60 - 62
[37] Merimepodib, Pegylated Interferon, and Ribavirin in Genotype 1 Chronic Hepatitis C Pegylated Interferon and Ribavirin Nonresponders
Rustgi, Vinod K.
Lee, William M.
Lawitz, Eric
Gordon, Stuart C.
Afdhal, Nezam
Poordad, Fred
Bonkovsky, Herbert L.
Bengtsson, Leif
Chandorkar, Gurudatt
Harding, Matthew
McNair, Lindsay
Aalyson, Molly
Alam, John
Kauffman, Robert
Gharakhanian, Shahin
McHutchison, John G.
HEPATOLOGY, 2009, 50 (06) : 1719 - 1726
[38] Primary hepatic lymphoplasmocytoid lymphoma, related to hepatitis C virus (HCV) infection responding to pegylated-interferon plus ribavirin therapy.
Lazzaro, A
Bernuzzi, P
Arcari, A
Vallisa, D
Anselmi, E
Berte, R
Civardi, G
Moroni, CF
Cavanna, L
BLOOD, 2003, 102 (11) : 304B - 304B
[39] Hemochromatosis Gene Mutations: Prevalence and Effects on Pegylated-Interferon and Ribavirin Therapy Response in Chronic Hepatitis C in Sardinia
Sini, Margherita
Sorbello, Orazio
Civolani, Alberto
Demelia, Luigi
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2012, 2 (03) : 211 - 217
[40] Hepatitis C Virus Genotype 1: How Genetic Variability of the Core Protein Affects the Response to Pegylated-Interferon and Ribavirin Therapy
Alhamlan, F. S.
Al-Ahdal, M. N.
Khalaf, N. Z.
Abdo, A. A.
Sanai, F. M.
Al-Ashgar, H. I.
ElHefnawi, M.
Zaid, A.
Al-Qahtani, A. A.
JOURNAL OF MEDICAL VIROLOGY, 2014, 86 (02) : 224 - 234

← 1 2 3 4 5 →